TELA Bio Reports Q3 2026 Revenue of $19.0 Million and $9.3 Million Net Loss
TELA Bio reported Q3 2026 revenue of $19.0M, down 8% YoY, and a net loss of $9.3M. Gross profit was $12.3M (64.9% margin). Adjusted EBITDA loss improved to $3.4M. The company reduced operating loss by 21% and implemented cost-cutting measures. International revenue grew 18% YoY, and the company gained market share in its hernia portfolio. TELA Bio also received 510(k) clearance for a new product and regained Nasdaq compliance.
How this was made
The 30-second read
Why it matters
Earnings miss may trigger short‑term price decline, but the new product clearance and cost cuts could support longer‑term upside.
Market read
Micro‑cap earnings with a loss; likely short‑term downside but potential upside from cost cuts and product clearance.
What to watch
Regulatory 510(k) clearance for a new scaffold may unlock future revenue streams.
Background
TELA Bio is a small‑cap medical‑device company focused on hernia repair technologies.
Ticker impact
Q3 2026 earnings report shows revenue down 8% YoY and a net loss of $9.3M, indicating weaker performance.
downward pressure as investors price in the loss and revenue decline
The company posted a larger loss than the prior year and revenue contraction, which typically triggers sell‑offs in micro‑caps.
Market effects
Signals softness in the medical‑device niche for hernia repair products.
Limited to U.S. biotech micro‑cap space.
Minimal global impact.
Counterpoint
If the cost‑reduction initiative extends cash runway to 2028, the stock could be undervalued despite the loss.
Key entities
- companyTELA Bio
Medical‑device maker reporting Q3 2026 results.
